Date: 2013-10-30
Type of information: Grant
Company: Transgene
Investors: National Institutes of Health (NIH) (USA)
Amount:
Funding type: grant
Planned used: The funding will be used to advance Transgene’s tuberculosis (TB) immunotherapy program.
Others: * On October 30, 2013, Transgene has announced that it has been granted a sub-award from Emergent BioSolutions under its existing grant of approximately $5 million from the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH). The funding will be used to advance Transgene’s tuberculosis (TB) immunotherapy program.
Transgene’s TB program is focused on developing a targeted immunotherapeutic to treat active TB, including resistant TB, utilizing the Company’s core viral vector technology. These novel immunotherapeutics contain, among other elements, a large array of TB proteins expressed during all phases of both active and latent infection. An immunotherapy approach offers the potential, especially for patients whose disease has become resistant to treatment, to enhance the effectiveness of current antibacterial therapies by correcting the immune system’s faulty response to the disease. Several potential product candidates have been generated by Transgene and are currently being evaluated to determine the best candidate to advance into further development.
Transgene has entered into a collaboration with Emergent BioSolutions for cell line process development and manufacturing for Transgene’s TB development candidate. Emergent BioSolutions’ significant expertise in process development and manufacturing complements Transgene’s capabilities. Transgene retains all development and commercialization rights to candidates generated under this NIAID-funded program.
Therapeutic area: Infectious diseases
